Building on the success of the adoptive immunotherapy of cancer

$3,013,441ZIAFY2019CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Paper 32571843 Paper 32461371 Paper 32291416 Paper 32060274 Paper 31996390 Paper 31959992 Paper 31959727 Paper 31196981 Paper 30712990 Paper 30392958 Paper 29426897 Paper 29379213 Paper 29326263 Paper 28683298 Paper 28576921 Paper 28530713 Paper 28412583 Paper 28008916 Paper 27965307 Paper 27829132 Paper 27803044 Paper 27757294 Paper 27716501 Paper 27626381 Paper 27565342 Paper 27271569 Paper 27217459 Paper 27158840 Paper 26885368 Paper 26822578 Paper 26735408 Paper 26731475 Paper 26701267 Paper 26674251 Paper 26657860 Paper 26137416 Paper 26018935 Paper 25998054 Paper 25939491 Paper 25838374 Paper 25728990 Paper 25695689 Paper 25686607 Paper 25640991 Paper 25537519 Paper 25446821 Paper 25432172 Paper 25384948 Paper 25358764 Paper 25061170 Paper 24827921 Paper 24694017 Paper 24661777 Paper 24336101 Paper 24329803 Paper 24114780 Paper 23650429 Paper 23633494 Paper 23601686 Paper 23576742 Paper 23568260 Paper 23377668 Paper 23349370 Paper 23302931 Paper 23290132 Paper 23281401 Paper 23222456 Paper 23207483 Paper 23090074 Paper 22996603 Paper 22972494 Paper 22932225 Paper 22869182 Paper 22723522 Paper 22721837 Paper 22555659 Paper 22437939 Paper 22420641 Paper 22291136 Paper 22057288 Paper 22056381 Paper 22011439 Paper 21926977 Paper 21900253 Paper 21795385 Paper 21737507 Paper 21499127 Paper 21498393 Paper 21327636 Paper 21305379 Paper 21285960 Paper 21282551 Paper 21198663 Paper 21157437 Paper 21149604 Paper 21084750 Paper 21075303 Patent 9522948 Patent 8613932 Patent 8216565

Abstract

Adoptive immunotherapy for cancer: building on success. Substantial progress has been made in our understanding of the molecular and cellular bases of T cell mediated anti-tumor responses. T cells are potent effectors of the adaptive anti-tumor immune response. Some target antigens recognized by tumor-reactive CD8+ T cells are mutated antigens. The molecular signals that modulate T cell activation, function and memory are being elucidated. Both positive and negative signals from co-stimulatory molecules have been shown to shape the anti-tumor response. Cytokines, including those with receptors that contain the common cytokine-receptor gamma chain have been shown to alter the programming of effector CD8+ T cells. We are also characterizing the metabolic characteristics of T cells that are capable of destroying tumor. In addition, we have studied the mechanisms that tumor cells use to escape recognition by T cells. This year we our study led by scientists in the Center for Cancer Research (CCR) at the National Cancer Institute shed light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer treatment.

View original record on NIH RePORTER →